Revance Presents Results of DaxibotulinumtoxinA for Injection in P-III ASPEN-1 Trial for the Treatment of Cervical Dystonia at AAN2021

 Revance Presents Results of DaxibotulinumtoxinA for Injection in P-III ASPEN-1 Trial for the Treatment of Cervical Dystonia at AAN2021

Revance Presents Results of DaxibotulinumtoxinA for injection in P-III ASPEN-1 trial for the Treatment of Cervical Dystonia at AAN2021

Shots:

  • The P-III ASPEN-1 trial evaluating the efficacy and safety of DaxibotulinumtoxinA (either 125 unit or 250 unit dose) for injection vs PBO in adults with cervical dystonia, patients followed for a maximum of 36 wks in post-treatment
  • The results showed median duration effect of up to 24 wks, as determined by time to loss of 80% peak treatment benefit, and has the potential to reduce frequency up to 50% annually, generally safe and well-tolerated
  • The trial underscores the potential of therapeutics pipeline for the treatment of muscle movement and pain disorders

Click here to­ read full press release/ article | Ref: BusinessWire | Image: Revance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post